drugset / Trial / NCT00692146

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

NCT00692146

Phase 1 Completed 36 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindTreatment

Summary

A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers

Timeline

Start
2008-01
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1386 Small molecule 95 mg Oral

Indications

No indication recorded.